Beyond the Dual Pathway Model: Evidence for the Dissociation of Timing, Inhibitory, and Delay-Related Impairments in Attention-Deficit/Hyperactivity Disorder

 This research was funded in part by ESRC CASE Award PTA-033-2003-00046 with Eli Lilley Ltd (to E.S.-B. and M.T. for P.B.).

 Clinical data from the participants included in this paper contributed to the IMAGE project (Faraone; National Institutes of Health grant R01 MH62873-01A1).

 Disclosure: Dr. Sonuga-Barke has served on the speakers' bureau and as a consultant for Shire and UCB Pharma. He has received research support from Janssen Cilag, Shire, Qbtech, and Flynn Pharma. He has served on the advisory board for Shire, Flynn Pharma, UCB Pharma, and Astra Zeneca. He has received conference support from Shire. Dr. Thompson has received education sponsorship from Eli Lilly and Janssen Cilag. She has received unrestricted research grants from Eli Lilly, Janssen Cilag, UCB Pharma, and Shire. She has served on the advisory board for Eli Lilly, UCB Pharma, and Shire. She has received drug trial support from Eli Lilly and Janssen Cilag. She has received lecture fees from Eli Lilly and Janssen Cilag. She has received funding for the support of Ph.D. students from Eli Lilly and Janssen Cilag. Dr. Bitsakou reports no biomedical financial interests or potential conflicts of interest.

PII: S0890-8567(10)00074-2

doi:10.1016/j.jaac.2009.12.018

© 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.